Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, has received a notice of acceptance from the National Medical Products Administration (NMPA) for the marketing authorization application of Edaravone Tablets, aimed at treating acute ischemic stroke (AIS) [1][2][3] Drug Information - Drug Name: Edaravone Tablets - Application Type: Domestic production drug registration and marketing authorization - Registration Category: Chemical drug category 2.2 - Specification: 30mg - Indication: Improvement of neurological symptoms and functional impairments caused by acute ischemic stroke, enhancing daily living capabilities [1] R&D and Registration Status - Edaravone is a novel free radical scavenger that has been shown to inhibit lipid peroxidation and endothelial cell damage, improving brain edema and tissue damage while delaying neuronal death [1][2] - The oral tablet formulation (TTYP01) is a modified new drug that does not require professional medical personnel for administration, allowing for self-administration by patients and better storage conditions [2] - The clinical trial for TTYP01 was completed in June 2024, demonstrating efficacy and safety comparable to the injectable form while improving patient compliance [2][3] Impact on the Company - The approval of Edaravone Tablets is expected to enhance the company's cardiovascular product pipeline and create synergies with existing products [3] - The drug's unique oral formulation and extended treatment duration may address urgent clinical needs in stroke management, potentially positioning it as a significant player in the market [2][3] - The acceptance of the marketing authorization application is a critical milestone in the drug's development, although it will not have a significant immediate impact on the company's current performance [3]

Group 1: Company Performance - Ningde Times reported a net profit of 30.5 billion yuan for the first half of the year, representing a year-on-year increase of 33.02% [1] - The company achieved revenue of 178.9 billion yuan, an increase of 7.27% compared to the same period last year [1] - Gross profit reached 44.8 billion yuan, up 14.45% year-on-year, with a gross margin of 25.02%, an increase of 1.57 percentage points from the previous year [1] Group 2: Stock Trading and Suspensions - Shangwei New Materials announced a suspension of trading due to multiple instances of abnormal stock price fluctuations, with the suspension expected to last no more than three trading days [2] - Jinchengzi is planning to acquire 55% of Samit Optoelectronics, leading to a stock suspension for up to ten trading days [3] - Sanchao New Materials is also planning a change in control, resulting in a stock suspension for up to two trading days [6] - Hehua Co. announced a stock suspension due to potential changes in its controlling shareholder [9] Group 3: Major Investments and Projects - Changjiang Electric Power plans to invest approximately 26.6 billion yuan in the construction of the Gezhouba Navigation Capacity Expansion Project [5] - The company will use its own funds for this investment, with the final amount to be confirmed based on state-approved preliminary design estimates [5] Group 4: Other Corporate Actions - Sunshine Dairy's controlling shareholder sold a total of 1.1452 million shares, accounting for 0.41% of the company's total share capital, without triggering any significant changes in control [4] - Nanjing Pharmaceutical is in the process of planning the acquisition of a domestic pharmaceutical technology asset group, with uncertainty regarding whether it constitutes a major asset restructuring [7]

Core Viewpoint - Huadong Medicine announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received the Acceptance Notification from the National Medical Products Administration (NMPA) for the marketing authorization application of Edaravone Tablets (R&D code: TTYP01) for the treatment of acute ischemic stroke [1] Group 1 - The application for Edaravone Tablets has been officially accepted by the NMPA [1] - The acceptance of the application marks a significant step towards potential commercialization of the drug [1] - The drug is specifically aimed at treating acute ischemic stroke, indicating a focus on critical healthcare needs [1]

Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., has received a notice of acceptance from the National Medical Products Administration for the marketing authorization application of Edaravone tablets for the treatment of acute ischemic stroke [1] Company Summary - Edaravone is a novel free radical scavenger that has been shown to inhibit lipid peroxidation and endothelial cell damage, improve brain edema, tissue injury, and delay neuronal death [1] - The mechanism of Edaravone involves reacting with oxygen free radicals closely related to ischemic brain injury, providing protective effects against brain ischemic damage [1]

Group 1 - The core point of the article highlights the performance and holdings of the Industrial Bank's Frontier Medical Stock C fund, which has shown significant returns over various time frames [1] - As of July 30, 2025, the latest net value of the fund is 3.3890 yuan, reflecting a decrease of 0.73%. The fund's one-month return is 14.49%, six-month return is 33.90%, and year-to-date return is 31.97% [1] - The top ten holdings of the fund account for a total of 59.44%, with significant positions in companies such as Heng Rui Pharmaceutical (9.51%), Kelun Pharmaceutical (9.16%), and Xinli Tai (6.70%) [1] Group 2 - The Industrial Bank's Frontier Medical Stock C fund was established on November 23, 2020, and as of June 30, 2025, it has a total scale of 1.26 billion yuan [1] - Zhao Bei serves as the fund manager and has extensive experience in the healthcare sector, having held various positions within the Industrial Bank since 2010 [2]

Group 1 - The core point of the article highlights the performance and holdings of the Industrial and Commercial Bank of China (ICBC) Healthcare Stock Fund, which has shown significant returns over various time frames [1] - As of July 30, 2025, the latest net value of the ICBC Healthcare Stock Fund is 2.9710 yuan, reflecting a decrease of 0.74% [1] - The fund's one-month return is 13.74%, ranking 90 out of 725 in its category; the six-month return is 31.81%, ranking 76 out of 709; and the year-to-date return is 30.36%, ranking 91 out of 705 [1] Group 2 - The top ten holdings of the ICBC Healthcare Stock Fund account for a total of 44.59%, with significant positions in companies such as Heng Rui Pharmaceutical (7.52%), Kelun Pharmaceutical (6.50%), and BeiGene (5.08%) [1] - The fund was established on November 18, 2014, and as of June 30, 2025, it has a total scale of 2.797 billion yuan [1] - The fund is managed by Zhao Bei and Ding Yang, both of whom have extensive experience in the healthcare sector [2]

Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, has received a notice of acceptance from the National Medical Products Administration (NMPA) for the marketing authorization application of Edaravone tablets for the treatment of acute ischemic stroke [1] Company Summary - The application for Edaravone tablets, with the development code TTYP01, has been officially accepted by the NMPA [1] - Edaravone is a novel free radical scavenger that has been shown to inhibit lipid peroxidation and endothelial cell damage, improve brain edema, tissue injury, and delay neuronal death [1] - The mechanism of Edaravone involves reacting with oxygen free radicals closely related to ischemic brain injury, providing protective effects against brain ischemic damage [1]

Core Viewpoint - Huadong Medicine's subsidiary, Sino-American Huadong, has received a notice of acceptance from the National Medical Products Administration for its application to market edaravone tablets for the treatment of acute ischemic stroke [1] Group 1: Company Developments - The application for edaravone tablets (R&D code: TTYP01) has been officially accepted, indicating progress in the drug approval process [1] - Edaravone is considered a significant drug in the neurology field, highlighting the company's focus on innovative treatments [1] Group 2: Industry Implications - The oral formulation of edaravone tablets is expected to reduce the consumption of medical resources compared to the intravenous administration of edaravone, which is typically given in hospitals for 14 days [1] - The ability for patients to self-administer the oral tablets may enhance treatment adherence and improve patient outcomes in the long term [1]

证券代码：000963 证券简称：华东医药 公告编号：2025-077 华东医药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025年07月30日，华东医药股份有限公司（以下简称"公司"）全 资子公司杭州中美华东制药有限公司（以下简称"中美华东"）收到国 家药品监督管理局（NMPA）签发的《受理通知书》（受理号： CXHS2500088），由中美华东申报的依达拉奉片（研发代码： TTYP01）用于治疗急性缺血性脑卒中的上市许可申请获得受理。现 将有关详情公告如下： 一、该药物基本信息内容 药物名称：依达拉奉片 规格：30mg 申报适应症：改善急性缺血性脑卒中（Acute Ischemic Stroke, AIS） 所致的神经症状和功能障碍，提高日常生活能力。 申请人：杭州中美华东制药有限公司 结论：根据《中华人民共和国行政许可法》第三十二条的规定， 经审查，决定予以受理。 申请事项：境内生产药品注册上市许可 注册分类：化学药品2.2类 二、该药物研发及注册情况 第 1 页 共 3 页 依达拉奉是一种 ...

Core Viewpoint - Huadong Medicine (000963) announced that its wholly-owned subsidiary, Sino-American Huadong, has had its application for the marketing authorization of Edaravone tablets for the treatment of acute ischemic stroke accepted by the National Medical Products Administration [1] Group 1: Product Development - Edaravone tablets are a new type of free radical scavenger aimed at improving neurological symptoms and functional impairments in stroke patients [1] - Compared to the existing Edaravone injection, the oral tablet form is more convenient for self-administration by patients [1] Group 2: Licensing and Investment - Sino-American Huadong has signed an exclusive licensing agreement with AusBio, acquiring the rights for the development, registration, production, and commercialization of the drug in mainland China and the Hong Kong, Macau, and Taiwan regions [1] - The company has invested approximately 101 million yuan in this project, including an upfront payment of 100 million yuan for project introduction [1]